Esperion Therapeutics Inc
What Spark Therapeutics’ Valuation Trend Indicates
Spark Therapeutics’ (ONCE) operating expenses decreased from $78.48 million in Q2 2017 to $59.78 million in Q2 2018.
Analyzing Axovant Sciences’ Valuation Metrics
In September, there are seven analysts covering Axovant Sciences (AXON) stock. Two of them have given it a “buy” rating, and five have given it a “hold.”
Analyzing the Research Pipeline of Esperion Therapeutics
Esperion Therapeutics’ development program for bempedoic acid consists of four clinical studies.